A 55-Year-Old Man with EGFR-mutated Advanced/Metastatic NSCLC

An expert discusses the case of a 55-year-old man with EGFR-mutated advanced/metastatic NSCLC, focusing on treatment considerations and management strategies.

Now Viewing

EP: 1.A 55-Year-Old Man with EGFR-mutated Advanced/Metastatic NSCLC

EP: 2.Recent Advances in First-Line Combination Therapy for EGFR-mutated Metastatic NSCLC: Exploring Amivantamab + Lazertinib and Osimertinib-Based Regimens

EP: 3.An Academic Perspective to Making First-Line Treatment Decisions for EGFR-mutated Metastatic NSCLC

EP: 4.First-Line Treatment Approaches for EGFR-mutated Metastatic NSCLC: Updates from MARIPOSA High-Risk Analyses

EP: 5.Management of Adverse Events with First-Line Combination Therapies for EGFR-mutated NSCLC

EP: 6.Considerations for Treatment of Advanced/Metastatic EGFR-mutated NSCLC

Recent Videos